EHA: European Hematology Association

Conference Coverage

Umbralisib can revitalize ruxolitinib in MF

STOCKHOLM—The PI3K delta inhibitor umbralisib can “augment or resurrect” responses to ruxolitinib in patients with myelofibrosis (MF), according...

Conference Coverage

CTL019 produces responses in rel/ref DLBCL

The chimeric antigen receptor (CAR) T-cell therapy CTL019 produced a high response rate in a phase 2 trial of adults with relapsed/refractory...

Pages